SFI
AUPH icon

Susquehanna Fundamental Investments’s Aurinia Pharmaceuticals AUPH Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,001
Closed -$89.8K – 1074
2024
Q4 		$89.8K Buy
+10,001
New +$81.6K ﹤0.01% 1041

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna Fundamental Investments's AUPH Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 10,001 shares — an estimated $89.8K sold.

Susquehanna Fundamental Investments first reported a position in AUPH in Q4 2024 and held it in 1 quarter. The position peaked at $89.8K in Q4 2024. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

  • Susquehanna Fundamental Investments reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 10,001 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $89.8K.
  • Susquehanna Fundamental Investments first reported a position in Aurinia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Aurinia Pharmaceuticals position peaked at $89.8K in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.